2023 ABAI Continuous Assessment Program - Block Two

The ABAI Continuous Assessment Program serves the need of board certified allergist/immunologists by allowing them to demonstrate their ongoing competence in the field. The program requires allergy/immunology specialists to read and successfully answer three review questions on each of 10 peer­ reviewed articles in the field every six months, along with correctly answering 10 multiple choice question on core topic areas in the specialty.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and  California Society of Allergy, Asthma & Immunology (CSAAI). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Board­ certified allergist/immunologists

Learning Objectives

At the conclusion of this activity, participants should be able to:

1. Outline the major literature published in the specialty during the past 12­24 months 
2. Demonstrate mastery of core knowledge central to the practice of allergy/immunology

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

No commerical support was received for this activity.

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Course opens: 
08/15/2023
Course expires: 
12/31/2023
Rating: 
5

All relevant financial relationships with ineligible companies have been mitigated.
 
Len Bacharier, MD, Planner
Consultant: Avillion, DBV, Kinaset, OM Pharma; Speaker: AstraZeneca, GSK, Novartis, Sanofi, Regeneron; DSMB: DBV; Advisory Board: Regeneron

Theresa Bingemann, MD, Planner
Consultant: Aimmune, ALK; Researcher: Novartis; Speaker: Sanofi

Christina Ciaccio, MD, Planner
Consultant: ALK, AstraZeneca, DBV, Genentech, Novartis, Sanofi-Genzyme; Advisory Board: Siolta; Speaker: Aimmune

Jeffrey Demain, MD, Planner
Advisory Board: Cogent Biosciences, Octapharma, Sanofi-Regeneron; Speaker: Blueprint Medicine

Hal Hoffman, MD, Planner
Consultant: Novartis; Research: Takeda, Zomagen, AB2Bio, Genentech

Giselle Mosnaim, MD, Planner
Research: Genentech, Sanofi-Regeneron, GSK, Novartis, Teva; Consultant: Novartis

Princess Ogbogu, MD, Planner
Advisory Board: AstraZeneca, GSK, Sanofi; Research: AstraZeneca, GSK, Blueprint Medical

Wanda Phipatanakul, MD, Planner
Advisory Board: AstraZeneca, Genentech, GSK, Novartis, Sanofi-Regeneron, Teva; Research: Genentech, Novartis, Sanofi-Regeneron, ALK, Circassia, Lincoln Diagnostics, Monaghan, ThermoFisher

David Bernstein, MD, Test Writer
Research: ALK, Regeneron, AstraZeneca, Bellus, Cheisi, GSK, IQVIA, Leo, Sanofi, Teva, ARS; Consultant: Gerson Lehman, ARS, Alpha Insights
Speaker: ALK; Advisory Board: Regeneron, Aquestive

Jonathan Bernstein, MD, Test Writer
Consultant: Eli Lilly, Escient, Jasper Therapeutics, ONO Pharmaceuticals, TLL Pharma, ALK, Allakos, AstraZeneca, BioCryst, Biomarin, Blueprint Medicines, CSL Behring, Elsevier, Celldex Therapeutics, Allergy Therapeutics, Sanofi-Regeneron, Shire/Takeda, Ionis, Kalvista, Merck, Novartis, Genentech, Opinose, Pharming; Speaker: GSK; Research: Teva, AstraZeneca, Ionis, Amgen

Kanwaljit Brar, MD, Test Writer
Consultant: Incyte

Neema Izadi, MD, Test Writer
Researcher: Teva

Michael Land, MD, Test Writer
Researcher: Quest Diagnostics

Jay Lieberman, MD, Test Writer
Advisory Board: ALK, Abbvie, Genentech, Aquestive, Novartis; Researcher: Aimmune, Regeneron, Abbvie; Adjudication DBV: Abbvie

Lindsey Moore, MD, Test Writer
Speaker: Aimmune; Researcher: Kenota

Anil Nanda, MD, Reviewer, Test Writer
Speaker: Sanofi

Thanai Pongdee, MD, Test Writer
Advisory Board: Blueprint Medicines; Consultant: GSK; Researcher: GSK

Christopher Randolph, MD, Test Writer
Speaker: Amgen, AstraZeneca, Boehringer Ingelheim, Grifols, Pfizer, GSK, Regeneron-Sanofi Adventis

Jeffrey Stokes, MD, Test Writer
Researcher: Sanofi, Regeneron

Dana Wallace, MD, Test Writer
Consultant: Bryn Pharma; Advisory Board: Sanofi, Abbvie

Julie Wang, MD, Test Writer
DMC Member: ALK; Consultant: Jubilant HollisterSteir; Researcher: Aimmune, DBV, Regeneron

The following have no relevant financial relationships with ineligible companies to disclose:

Marianna Castells, MD, Planner 
Karla Adams, MD, Reviewer, Test Writer 
Jack Becker, MD, Test Writer 
Matt Bell, MD, Test Writer
Scott Feldman, MD, Test Writer
Corinne Keet, MD, Test Writer
Mitchell Lester, MD, Test Writer
Aidan Long, MD, Test Writer
Cecelia Mikita, MD, Test Writer
Michael Nelson, MD, Test Writer
Pavadee Poowuttikul, MD, Test Writer
Rebecca Scherzer, MD, Test Writer

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Please login or create an account to take this course.